Usefulness of Cernilton in the treatment of benign prostatic hyperplasia

Int Urol Nephrol. 1996;28(1):49-53. doi: 10.1007/BF02550137.


A total of 89 patients with benign prostatic hyperplasia (BPH) were treated pharmacologically for 4 months: 51 received Cernilton and 38 Tadenan (controls). Significant subjective improvement was found in 78% of the patients in the Cernilton group compared to only 55% of the Tadenan-treated patients. The obstructive and irritative symptoms responded best to the therapy. In the Cernilton-treated patients a significant improvement in the uroflow rate, decrease in residual urine and in prostate volume were found. This study shows that Cernilton is an effective therapy for patients with BPH.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Aged
  • Fatty Alcohols / therapeutic use
  • Humans
  • Male
  • Middle Aged
  • Plant Extracts / therapeutic use*
  • Prostate / diagnostic imaging
  • Prostatic Hyperplasia / diagnostic imaging
  • Prostatic Hyperplasia / drug therapy*
  • Prostatic Hyperplasia / physiopathology
  • Secale
  • Ultrasonography
  • Urodynamics


  • Fatty Alcohols
  • Plant Extracts
  • Tadenan
  • cernilton